Viewing nowDiozartan Tablets 80mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Boryung Biopharma Co., Ltd.

MFDS item code 201901299 · Approved 2019.03.01 · Insurance code 670501410
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
This medication is used to control blood pressure in patients with essential hypertension. It also helps improve symptoms and maintain heart function in heart failure patients who are intolerant to ACE inhibitors. It is effective in reducing the risk of death in clinically stable patients with left ventricular dysfunction or reduced contraction function after myocardial infarction. Thus, it is used for hypertension, heart failure, and post-myocardial infarction management.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medication be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medication once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medication once daily, and do not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. However, this medication should not be administered to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: The daily dose of this medication should preferably not exceed 80 mg in patients with mild to moderate hepatic impairment. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
6) Pediatrics: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatrics: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters. It must be discontinued as soon as pregnancy is confirmed. Women who are pregnant or may become pregnant, breastfeeding women, patients with severe liver impairment, patients with significantly reduced kidney function, and patients with hereditary angioedema should not use this medication. Caution is advised for elderly patients, patients with hyperkalemia, patients with liver disorders, patients with heart valve diseases, and patients with cardiovascular diseases as they may experience low blood pressure or changes in kidney function. This medication may cause a sudden drop in blood pressure after the first dose, so patients who are particularly low on fluids or sodium, those taking diuretics, or those undergoing dialysis should start with a low dose and be closely monitored. Patients with high serum potassium levels or those at risk of hyperkalemia should regularly check their potassium levels during this medication and be cautious when taking potassium supplements or potassium-sparing diuretics. This medication may interact with other antihypertensives or specific drugs, so any medications being taken must be discussed with healthcare professionals. Dizziness or drowsiness may occur, so caution is needed when driving or operating machinery. Pregnant or breastfeeding women should avoid taking this medication, and if unavoidable, must consult a specialist. Safety and efficacy in children and adolescents have not been established, so its use is not recommended. In case of overdose, symptoms such as low blood pressure and decreased consciousness may occur, requiring immediate emergency care. This medication should be kept out of reach of children and should not be transferred to other containers.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its efficacy.
Light pink, double convex, round film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Boryung Biopharma Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.